Pathophysiology
Loss of contractile function activates RAAS and sympathetic systems; adverse remodelling. Ischaemia, hypertension, valvular disease, viral, toxic (alcohol, chemo), genetic aetiologies.
Sources: AHA/ACC HF 2022 (Circulation 2022;145:e895); DAPA-HF (NEJM 2019;381:1995)
Presentation
Dyspnoea on exertion, orthopnoea, PND, fatigue, oedema, elevated JVP, S3, bibasilar crackles, cool extremities.
Diagnosis
BNP/NT-proBNP elevated; echocardiogram (LVEF <=40%); ECG; CMR or angiography for aetiology.
Management
Four pillars simultaneously: ARNI (sacubitril/valsartan) or ACEi/ARB, beta-blocker (carvedilol, metoprolol succinate, bisoprolol), MRA (spironolactone/eplerenone), SGLT2 inhibitor (dapagliflozin/empagliflozin). Diuretics for congestion. ICD if LVEF <=35% despite GDMT. CRT if LBBB QRS >=150.






